Sign In
Buy ALGS
$5.14
-0.110 (-2.10%)
At Close: Jun 03, 2026
Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024
01:30pm, Tuesday, 19'th Nov 2024
SOUTH SAN FRANCISCO, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeuti
Aligos Therapeutics, Inc. (ALGS) Reports Q3 Loss, Tops Revenue Estimates
07:06pm, Wednesday, 06'th Nov 2024
Aligos Therapeutics, Inc. (ALGS) came out with a quarterly loss of $3.07 per share versus the Zacks Consensus Estimate of a loss of $2.15. This compares to loss of $10.25 per share a year ago.
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results
04:05pm, Wednesday, 06'th Nov 2024
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on improving patient outcomes
Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting
08:30am, Thursday, 31'st Oct 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #alagillesyndrome--Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting .
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:00am, Friday, 11'th Oct 2024
SOUTH SAN FRANCISCO, Calif., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving pa
Aligos Therapeutics Appoints David Perry as Vice President of Business Development
08:00am, Tuesday, 01'st Oct 2024
SOUTH SAN FRANCISCO, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in
Aligos Therapeutics to Present at Investor Conferences in October
08:00am, Monday, 30'th Sep 2024
SOUTH SAN FRANCISCO, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-
Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH
08:00am, Thursday, 19'th Sep 2024
SOUTH SAN FRANCISCO, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-i
Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024
05:00pm, Wednesday, 18'th Sep 2024
SOUTH SAN FRANCISCO, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving p
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:00am, Friday, 13'th Sep 2024
SOUTH SAN FRANCISCO, Calif., Sept. 13, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving p
Are Medical Stocks Lagging Aligos Therapeutics (ALGS) This Year?
10:46am, Tuesday, 10'th Sep 2024
Here is how Aligos Therapeutics, Inc. (ALGS) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year.
How Much Upside is Left in Aligos Therapeutics (ALGS)? Wall Street Analysts Think 648.14%
10:55am, Wednesday, 21'st Aug 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 648.1% in Aligos Therapeutics (ALGS). While the effectiveness of this highly sought-after metric is questionabl
Aligos Therapeutics Announces Reverse Stock Split
09:00am, Thursday, 15'th Aug 2024
SOUTH SAN FRANCISCO, Calif., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on developing n
What Makes Aligos Therapeutics (ALGS) a New Buy Stock
01:01pm, Friday, 09'th Aug 2024
Aligos Therapeutics (ALGS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Aligos Therapeutics Strengthens Board with Two New Independent Directors
04:05pm, Thursday, 08'th Aug 2024
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, the “Company”), a clinical stage biopharmaceutical company focused on develo
